Sulaiman Bani Abdel-Rahman

Dr. Sulaiman Bani Abdel-Rahman

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
OAOhood Salem Alharbi
Ohood Salem Alharbi
KAKhulud Alhazmi
Khulud Alhazmi
MGMalaz Gazzaz
Malaz Gazzaz
SASarah Almuhayya
Sarah Almuhayya
FAFaye Aldehalan
Faye Aldehalan
KIKarem Ibrahem
Karem Ibrahem
Biofilm-associated infections pose a significant challenge in clinical settings due to their increased resistance to antibiotics and evasion of host immune responses. These infections are responsible for a large proportion of chronic and recurrent infections, leading to prolonged hospital stays, increased healthcare costs, and elevated morbidity and mortality rates. Vancomycin, a glycopeptide antibiotic, has long been a cornerstone in the treatment of infections caused by Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA). In addition, vancomycin-resistant Enterococcus (VRE) represents an important group of biofilm-forming pathogens, further complicating treatment strategies. However, its efficacy against biofilms remains a subject of ongoing research and debate. The ability of vancomycin to target biofilm-embedded bacteria is often hindered by multiple resistance mechanisms, including poor antibiotic penetration, metabolic adaptation of biofilm-associated cells, and the presence of persister cells. The aim of this review is to evaluate vancomycin’s antibiofilm activity by examining its mechanism of action, pharmacokinetics, effectiveness, limitations, and potential strategies to enhance its therapeutic outcomes. Several novel approaches have been explored to augment vancomycin’s antibiofilm activity, including combination therapies, adjuvant strategies, and nanotechnology-based drug delivery systems. Understanding these factors is crucial for optimizing therapeutic strategies and overcoming the persistent challenge of biofilm-related infections. This review synthesizes current evidence and highlights areas requiring further research to enhance vancomycin’s efficacy against biofilm-associated infections.

1 May 2026 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
SASulaiman Bani Abdel-Rahman
Sulaiman Bani Abdel-Rahman
HAHala Altarawneh
Hala Altarawneh
HAHassan Ahmad Hasan Alfreahat
Hassan Ahmad Hasan Alfreahat
KAKhulud Alhazmi
Khulud Alhazmi
OAOhood Salem Alharbi
Ohood Salem Alharbi
KIKarem Ibrahem
Karem Ibrahem
Klebsiella pneumoniae is a major opportunistic pathogen responsible for a wide range of hospital- and community-acquired infections, including respiratory tract infections, urinary tract infections, meningitis, and liver abscesses. Among its emerging forms, hypervirulent K. pneumoniae (hvKp) has gained global attention due to its heightened virulence and ability to cause severe infections in healthy individuals. hvKp differs from classical K. pneumoniae (cKp) in its clinical presentation, often causing metastatic infections, liver abscesses without biliary disease, and multiple-site involvement. Despite initial antibiotic susceptibility, the recent convergence of hvKp virulence traits with antimicrobial resistance genes—especially those conferring multidrug resistance (MDR) and carbapenem resistance—poses a serious therapeutic challenge. This review highlights the epidemiological and clinical distinctions between hvKp and cKp, emphasizing the limitations of current diagnostic markers like the string test. Furthermore, it explores novel therapeutic strategies beyond conventional antibiotics, focusing on promising alternatives such as bacteriophage therapy and antimicrobial peptides (AMPs). Several phages, including PSKP16, vB_Kpn_F13, and phage cocktails, have demonstrated potent activity against hvKp strains, including biofilm-forming and carbapenem-resistant isolates. Likewise, AMPs such as Osmin, AA139-nanoformulations, and scorpion venom-derived Cm38 show efficacy in preclinical models. These emerging approaches hold potential to combat the rising threat of hvKp, especially strains that are extensively drug-resistant. Continued research and investment are essential to translate these findings into clinical practice and ensure effective management of hypervirulent and resistant K. pneumoniae infections.

23 October 2025 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
WHWaiel Halabi
Waiel Halabi
SASulaiman Bani Abdel-Rahman
Sulaiman Bani Abdel-Rahman
HAHala Altarawneh
Hala Altarawneh
RARawan Altalhi
Rawan Altalhi
LILoui A Ismaeel
Loui A Ismaeel
KIKarem Ibrahem
Karem Ibrahem
Pandoraea species are emerging multidrug-resistant pathogens increasingly associated with respiratory tract infections, particularly in cystic fibrosis patients. Despite their growing clinical relevance, these bacteria are underrepresented in the scientific literature. This review aims to consolidate existing evidence regarding Pandoraea species as emerging multidrug-resistant pathogens, with a focus on their taxonomy, diagnostic methodologies, antimicrobial resistance mechanisms, and treatment challenges. By identifying gaps in current therapeutic strategies and the limited clinical outcome data, this review underscores the necessity of advancing research into innovative interventions, such as bacteriophages, antimicrobial peptides, and combination therapies, to enhance patient management and infection control. A comprehensive literature search was conducted using PubMed and Google Scholar, employing relevant keywords to identify case reports, clinical studies, and in vitro research related to Pandoraea infections, resistance mechanisms, and therapeutic strategies. Our findings reveal a significant lack of comprehensive data on therapeutic approaches, particularly concerning bacteriophages, antimicrobial peptides, and combination antibiotic therapies. Furthermore, clinical data on treatment efficacy remain sparse, with the majority of evidence stemming from in vitro studies rather than real-world clinical settings. This review emphasizes the urgent need for further research to address these knowledge deficits and to develop effective therapeutic interventions against Pandoraea infections.

31 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
KAKhulud Alhazmi
Khulud Alhazmi
SASulaiman Bani Abdel-Rahman
Sulaiman Bani Abdel-Rahman
HAHala Altarawneh
Hala Altarawneh
KIKarem Ibrahem
Karem Ibrahem
WHWaiel Halabi
Waiel Halabi
BJBasem Jawa
Basem Jawa
Background/Objectives: Early and accurate quantification of Human Immunodeficiency Virus type 1 (HIV-1) viral load is essential for monitoring antiretroviral therapy and guiding clinical management. Although conventional real-time polymerase chain reaction (PCR) platforms provide reliable viral load measurement, they often require centralized laboratories and longer turnaround times. Cartridge-based systems such as the GeneXpert HIV-1 Viral Load assay offer a simplified testing workflow and may facilitate decentralized molecular testing. This study aimed to evaluate the qualitative and quantitative agreement between the GeneXpert HIV-1 Viral Load assay and the Abbott Alinity m HIV-1 assay. Methods: A total of 102 residual clinical Ethylenediaminetetraacetic acid (EDTA) plasma specimens were analyzed using both the GeneXpert HIV-1 Viral Load assay and the Abbott Alinity m HIV-1 assay. Qualitative agreement was evaluated using positive percent agreement (PPA), negative percent agreement (NPA), overall agreement, and Cohen’s κ coefficient. Quantitative agreement among specimens with paired quantifiable viral load results was assessed using Pearson’s correlation and Bland–Altman analyses. Results: Overall qualitative agreement between the two assays was 95.1%, with a PPA of 92.6%, an NPA of 100.0%, and a Cohen’s κ coefficient of 0.894, indicating almost perfect agreement. Among the 57 specimens with paired quantifiable viral load results, a very strong positive correlation was observed (Pearson’s r = 0.9972; 95% CI: 0.9952–0.9984; p < 0.001). Bland–Altman analysis demonstrated a minimal mean bias of −0.018 log10 IU/mL, with 95% limits of agreement ranging from −0.175 to 0.139 log10 International Units per milliliter (IU/mL). All paired quantitative differences were within the clinically accepted agreement threshold of ±0.5 log10 IU/mL. Conclusions: The GeneXpert HIV-1 Viral Load assay demonstrated excellent qualitative and quantitative agreement with the Abbott Alinity m HIV-1 assay. These findings support the potential use of the GeneXpert HIV-1 Viral Load assay as an alternative testing platform for routine HIV-1 viral load monitoring in appropriate clinical settings.